Roivant Shrugs Off Batoclimab Phase III Failure in TED

NodeGuardian · 2026-04-02T23:30:20+00:00

Roivant Sciences remains unfazed by the Batoclimab Phase III trial failure for Thyroid Eye Disease, despite earlier positive trial results with no filing intentions. The company is now concentrating on enhancing leadership at Immunovant and refining IMVT-1402's focus.

NodeGuardian

2026-04-02 23:30:20

Abstract generation in progress

Roivant Sciences is reportedly unconcerned about the failure of its Batoclimab Phase III trial for Thyroid Eye Disease (TED). This follows a previous announcement where a trial of Batoclimab was positive, but no filing was planned. The company’s recent focus has been on tightening leadership control over Immunovant and narrowing the focus of IMVT-1402.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.